Is Lyra Therapeutics Inc (NASDAQ: LYRA) Stock An Instant Disaster Or An Incredible Opportunity?

In the last trading session, 14.09 million Lyra Therapeutics Inc (NASDAQ:LYRA) shares changed hands as the company’s beta touched 0.04. With the company’s per share price at $0.11 changed hands at $0.0 or -0.98% during last session, the market valuation stood at $7.40M. LYRA’s last price was a discount, traded about -281.82% off its 52-week high of $0.42. The share price had its 52-week low at $0.08, which suggests the last value was 27.27% up since then.

Analysts gave the Lyra Therapeutics Inc (LYRA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended LYRA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.

Lyra Therapeutics Inc (NASDAQ:LYRA) trade information

Instantly LYRA was in red as seen at the end of in last trading. With action 13.75%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -45.88%, with the 5-day performance at 13.75% in the green. However, in the 30-day time frame, Lyra Therapeutics Inc (NASDAQ:LYRA) is 21.41% up.

The consensus price target for the stock as assigned by Wall Street analysts is 0.5, meaning bulls need an upside of 78.0% from its current market value. According to analyst projections, LYRA’s forecast low is 0.5 with 0.5 as the target high. To hit the forecast high, the stock’s price needs a -354.55% plunge from its current level, while the stock would need to soar -354.55% for it to hit the projected low.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -2.22%. The 2025 estimates are for Lyra Therapeutics Inc earnings to increase by 55.94%, but the outlook for the next 5-year period is at 21.95% per year.

LYRA Dividends

Lyra Therapeutics Inc is expected to release its next quarterly earnings report in June.

CITADEL ADVISORS LLC holds the second largest percentage of outstanding shares, with 7.2912% or 4.77 million shares worth $1.32 million as of 2024-06-30.

Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 2.37 shares estimated at $0.26 million under it, the former controlled 3.57% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.50% of the shares, roughly 992.54 shares worth around $0.11 million.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.